Hospitals' compliance with prophylaxis guidelines for venous thromboembolism

American Journal of Health-System Pharmacy

Volumn 64, Issue 1, 2007, Pages 69-76

  Yu, Hsing Ting ^a   Dylan, Michelle L ^a   Lin, Jay ^b   Dubois, Robert W ^a,c  

^a CERNER CORPORATION   (United States)

^b SANOFI   (France)

^c CLS   (United States)

Author keywords

Anticoagulants; Compliance; Dosage; Hospitals; Protocols; Rational Therapy; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; FEMALE; GENERAL SURGERY; GYNECOLOGIC SURGERY; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; ORTHOPEDIC SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SPINE INJURY; TREATMENT DURATION; UROLOGIC SURGERY; VENOUS THROMBOEMBOLISM;

EID: 33947131145     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060115     Document Type: Article

References (38)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107:14-8.
2. Cundiff DK. Anticoagulation therapy thromboembolism. Med Gen Med. 2004; 6:5.
3. Hull RD, Feldstein W, Stein PD et al. Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med. 1996; 156:68-72.
4. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis. 1994; 36:417-22.
5. Clagett GP, Anderson FA Jr., Heit J et al. Prevention of venous thromboembolism. Chest. 1995; 108:3125-345.
6. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. The Multicenter Trial Committee. JAMA. 1984; 251:2960-6.
7. Kakkar W, Corrigan T, Spindler J et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet. 1972; 2:101-6.
8. Haas S, Flosbach CW. Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial. Eur J Surg Suppl. 1994; 571:37-43.
9. Turpie AG, Levine MN, Hirsh J et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986; 315:925-9.
10. Lassen MR, Borris LC, Christiansen HM et al. Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis. Semin Thromb Hemost. 1991; 17(suppl3):284-90.
11. Hoek JA, Nurmohamed MT, Hamelynck KJ et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost. 1992; 67:28-32.
12. Grilli R, Magrini N, Penna A et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000; 355:103-6.
13. Cluzeau FA, Littlejohns P, Grimshaw JM et al. Development and application of a generic methodology to assess the quality of clinical guidelines. Int J Qual Health Care. 1999; 11:21-8.
14. Bratzler DW, Raskob GE, Murray CK et al. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998; 158:1909-12.
15. Stratton MA, Anderson FA, Bussey HI et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med. 2000; 160:334-40.
16. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest. 2001; 119:132S-75S.
17. U. S. Department of Health and Human Services, Office for Civil Rights. HIPAA medical privacy-national standards to protect the privacy of personal health information. www.hhs.gov/ocr/hipaa/ bkgrnd.html (accessed 2005 Aug 21).
18. Department of Health and Human Services policy for protection of human research subjects. www.hhs.gov/ ohrp/humansubjects/guidance/45cfr46. htm#46.101 (accessed 2006 Jan 12).
19. Silverstein MD, Heit JA, Mohr DN et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158:585-93.
20. Lilienfeld DE. Decreasing mortality from pulmonary embolism in the United States, 1979-1996. Int J Epidemiol. 2000; 29:465-9.
21. Roos LL, Sharp SM, Cohen MM et al. Risk adjustment in claims-based research: the search for efficient approaches. J Clin Epidemiol. 1989; 42:1193-206.
22. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46:1075-9.
23. Ageno W, Squizzato A, Ambrosini F et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica. 2002; 87:746-50.
24. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001; 120:1964-71.
25. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 282:1458-65.
26. Conti S, Daschbach M. Venous thromboembolism prophylaxis: a survey of its use in the United States. Arch Surg. 1982; 117:1036-40.
27. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993; 329:1271-3.
28. Laverick MD, Croal SA, Mollan RA. Orthopaedic surgeons and thromboprophylaxis. BMJ. 1991; 303:549-50.
29. Unwin AJ, Jones JR, Harries WJ. Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty. Ann R Coll Surg Engl. 1995; 77:351-4.
30. Fonarow GC, French WJ, Parsons LS et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001; 103:38-44.
31. Allison JJ, Kiefe CI, Weissman NW et al. Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI. JAMA. 2000; 284:1256-62.
32. Anderson FA Jr., Wheeler HB, Goldberg RJ et al. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med. 1994; 154:669-77.
33. Anderson FA Jr., Wheeler HB, Goldberg RJ et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991; 115:591-5.
34. Winkler JD, Lohr KN, Brook RH. Persuasive communication and medical technology assessment. Arch Intern Med. 1985; 145:314-7.
35. Durieux P, Nizard R, Ravaud P et al. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA. 2000; 283:2816-21.
36. Williams HR, Macdonald DA. Audit of thromboembolic prophylaxis in hip and knee surgery. Ann R Coll Surg Engl. 1997; 79:55-7.
37. Kucher N, Koo S, Quiroz R et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352:969-77.
38. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). NQF, JCAHO to develop standards for care of deep vein thrombosis. www.healthynh. com/archive.php?expand=2004-09& subex=833 (accessed 2006 Mar 3).